Article

Second Webinar in the ISPOR-IVI Series Explores Whether Value Assessment Methods Are Up to the Task in the Age of COVID-19

The second of a 5-part webinar series examining value assessment in the COVID-19 era hosted by ISPOR and the Innovation and Value Initiative (IVI) will explore whether the methods on which health economists have relied are up to the task or in need of improvement for the pandemic era.

The second of a 5-part webinar series examining value assessment in the COVID-19 era hosted by ISPOR and the Innovation and Value Initiative (IVI) will explore whether the methods on which health economists have relied are up to the task or in need of improvement for the pandemic era.

Moderated by Lou Garrison, PhD; University of Washington, panelists Charles Phelps, PhD; University of Rochester; Anirban Basu, PhD; University of Washington; Susan Griffin, PhD; University of York; and Dan Ollendorf, PhD; Tufts Medical Center will discuss what changes in value assessment methods may be needed to assess value among rapidly developing interventions, including vaccines, treatments, tests, and non-medical care. 

“Our webinar series looks at value assessment through today’s pandemic lens to explore how it can be improved to meet the moment,” says Jennifer Bright, executive director, IVI. “This is an incredibly important and relevant discussion for all healthcare decision makers.” 

The webinar will be from 1:00 PM -2:15 PM EST on Thursday, August 27. Register for the webinar by clicking here www.ispor.org/webinars-COVID-IVI.Space is limited, so register today!

Related Videos
Robin Glasco, Spencer Stuart
Robin Glasco, MBA
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Matias Sanchez, MD
Screenshot of an interview with Nadine Barrett, PhD
Neil Goldfarb, GPBCH
Dr Bonnie Qin
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo